Alcon AG

President Donald Trump has secured new drug pricing agreements with nine pharmaceutical companies, bringing the total to 26 and covering 90% of the domestic pharmaceutical market. The companies include Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB, which will offer discounts on outpatient drugs across all state Medicaid programs. These deals, announced Monday, aim to align U.S. drug prices with international levels and cover treatments for chronic and rare conditions such as hemophilia, liver disease, skin disorders, and certain cancers. The companies have also committed to investing at least $19.6 billion in U.S. manufacturing, with Astellas, Sun Pharma, Teva, and UCB donating active pharmaceutical ingredients to the federal strategic reserve. Health and Human Services Secretary Robert F. Kennedy Jr. described his conversations with Trump as "very, very emotional," while White House economists estimate the deals could save $529 billion over the next decade, including $64.3 billion in Medicaid savings.

President Trump announced on Monday that his administration has signed separate drug-pricing agreements with nine mid-sized pharmaceutical companies, expanding his Most-Favored-Nation (MFN) pricing push beyond Big Pharma. The companies include Alcon, Astellas Pharma, BeOne Medicines, BridgeBio Pharma, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB, which have agreed to reduce prescription drug prices to match those in comparable developed countries. In return, they receive a reprieve from import tariffs on pharmaceutical ingredients, contingent on expanding domestic manufacturing, with a collective commitment of at least $19.6 billion in U.S. manufacturing. Some companies also agreed to contribute active pharmaceutical ingredients to a government stockpile reserve, such as Teva supplying 45 metric tons of metronidazole and UCB providing 163 tons of levetiracetam. With these additions, the total number of drugmakers with MFN agreements has risen to 26, covering 89% of the branded drug market, and the administration has called on Congress to codify the policy through the Great Healthcare Plan.

The Trump administration has struck new drug pricing agreements with nine biotech and pharmaceutical companies, including UCB SA, Bridgebio Pharma Inc., and Sun Pharmaceutical Industries Ltd., President Donald Trump announced Monday at the White House. The deals, which also include Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Alcon AG, BeOne Medicines Ltd., CSL Ltd., and Kyowa Kirin Co., will ensure that every drug is offered at the lowest prices available anywhere in the world. Trump claimed that these additions bring the total to 26 companies representing 90% of the domestic pharmaceutical market, with the remaining 10% expected to join. The agreements require companies to provide discounts on outpatient drugs to state Medicaid programs, aligning state prices with those charged in foreign countries, though participation by states is optional. This announcement follows earlier most-favored-nation deals with 17 large pharmaceutical companies, including Pfizer Inc. and Eli Lilly & Co., which agreed to reduce prices for federal health insurance programs in exchange for tariff relief. The deals do not address costs for the over 160 million Americans with employer-sponsored insurance, and researchers estimate that applying similar pricing to 82 high-cost brand-name drugs could save states more than $8 billion annually.

Glaukos shares have surged 67.9% year to date, significantly outperforming its industry's 8.4% decline and the S&P 500's 12% return, driven by accelerating operating momentum from the commercial ramp of iDose TR and the early launch of Epioxa. Second-quarter revenues jumped 49.5% to $185.6 million, prompting management to raise 2026 revenue guidance by $60-$65 million to $680-$700 million. U.S. glaucoma revenues increased 64% to $118.5 million, with iDose TR sales reaching approximately $74 million, up 37% sequentially, while the Corneal Health franchise grew 48% to $30.4 million, including roughly $11 million from Epioxa. The company is expanding internationally, with second-quarter international revenues up 17% to $36.6 million, and is advancing a diversified pipeline across five novel therapeutic platforms and 13 publicly disclosed programs. Key risks include reimbursement execution for iDose TR, early-stage Epioxa commercialization, and competitive pressures from Alcon, Sight Sciences, and AbbVie.

Alcon's new surgical platforms and lenses are gaining adoption, and dry eye momentum is expected to support growth, but adverse macroeconomic conditions and intense competition remain concerns. The company reported share gains in U.S. AT-IOLs and is preparing to launch an upgraded Vivity lens in early 2027, while continuing to scale Tryptyr and Systane in dry eye and broaden its contact lens lineup with TOTAL30 and PRECISION7. However, incremental tariffs in the United States and China totaled $33 million in the first quarter of 2026, creating a 120 basis points drag on core gross margin, and competition is intensifying outside the United States. The Zacks Consensus Estimate for 2026 earnings per share has remained unchanged at $3.48 over the past 30 days, with revenues pegged at $11.06 billion, suggesting a 7.2% rise from the prior year. Alcon stock has dipped 25.1% over the past year, compared with a 10.4% decline for the industry and a 23.9% rise for the S&P 500.

Johnson & Johnson is spending more than $1 billion to expand its Vision manufacturing, packaging, and distribution facilities in Jacksonville, Florida. The expansion is part of a broader $55 billion U.S. investment initiative focused on manufacturing and R&D. The Jacksonville site will scale domestic production capacity for ACUVUE contact lenses using advanced manufacturing technologies. The commitment deepens the company's presence in eye care, where it competes with Alcon and Bausch + Lomb, and may tighten quality control while reducing exposure to global logistics issues.